tiprankstipranks
Advertisement
Advertisement

HK:2575 Stock Latest News

Xuanzhu’s Anaprazole Wins NMPA Review Nod for Reflux Esophagitis
Company AnnouncementsXuanzhu’s Anaprazole Wins NMPA Review Nod for Reflux Esophagitis
2d ago
2575
Xuanzhu Biopharma Advances Anaprazole into Phase III Trial for H. pylori Eradication
PremiumCompany Announcements
Xuanzhu Biopharma Advances Anaprazole into Phase III Trial for H. pylori Eradication
10d ago
2575
Xuanzhu Biopharmaceutical Shareholders Approve AGM Resolutions and Governance Overhaul
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Shareholders Approve AGM Resolutions and Governance Overhaul
13d ago
2575
Xuanzhu Biopharmaceutical Adds Employee Representative to Board as Executive Director Resigns
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Adds Employee Representative to Board as Executive Director Resigns
13d ago
2575
Xuanzhu Biopharmaceutical updates board and committee roles
PremiumCompany Announcements
Xuanzhu Biopharmaceutical updates board and committee roles
13d ago
2575
Xuanzhu Biopharmaceutical Sets 2025 AGM With Governance and Capital Mandates on Agenda
PremiumCompany AnnouncementsXuanzhu Biopharmaceutical Sets 2025 AGM With Governance and Capital Mandates on Agenda
1M ago
2575
Xuanzhu Biopharmaceutical Overhauls Governance Structure and Board Composition
Premium
Company Announcements
Xuanzhu Biopharmaceutical Overhauls Governance Structure and Board Composition
1M ago
2575
Xuanzhu Biopharmaceutical Completes Full H-Share Circulation on HKEX
Premium
Company Announcements
Xuanzhu Biopharmaceutical Completes Full H-Share Circulation on HKEX
2M ago
2575
Xuanzhu Biopharma Posts Encouraging Early Data for NG-350A in Rectal Cancer
PremiumCompany Announcements
Xuanzhu Biopharma Posts Encouraging Early Data for NG-350A in Rectal Cancer
2M ago
2575
Xuanzhu’s ALK Inhibitor Dirozalkib Delivers Strong Phase III Results in First-Line Lung Cancer
PremiumCompany Announcements
Xuanzhu’s ALK Inhibitor Dirozalkib Delivers Strong Phase III Results in First-Line Lung Cancer
2M ago
2575
Xuanzhu Biopharmaceutical Wins Approval for Major H Share Full Circulation
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Wins Approval for Major H Share Full Circulation
3M ago
2575
Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori
PremiumCompany Announcements
Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori
3M ago
2575
Xuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan
PremiumCompany AnnouncementsXuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan
3M ago
2575
Xuanzhu Biopharm Licenses Key Cancer Drugs to Boston Oncology for MENA Expansion
Premium
Company Announcements
Xuanzhu Biopharm Licenses Key Cancer Drugs to Boston Oncology for MENA Expansion
3M ago
2575
Xuanzhu Biopharmaceutical Narrows Annual Loss on Surging Revenue and Deep Cost Cuts
Premium
Company Announcements
Xuanzhu Biopharmaceutical Narrows Annual Loss on Surging Revenue and Deep Cost Cuts
3M ago
2575
Xuanzhu’s Breast Cancer Drug Bireociclib Delivers Strong Phase 3 Results Published in JAMA Oncology
PremiumCompany Announcements
Xuanzhu’s Breast Cancer Drug Bireociclib Delivers Strong Phase 3 Results Published in JAMA Oncology
3M ago
2575
Xuanzhu Biopharm Completes Phase III Patient Enrollment for Anaprazole in Reflux Esophagitis
PremiumCompany Announcements
Xuanzhu Biopharm Completes Phase III Patient Enrollment for Anaprazole in Reflux Esophagitis
3M ago
2575
Xuanzhu Biopharmaceutical Sets March 30 Board Meeting for 2025 Results and Dividend Decision
PremiumCompany Announcements
Xuanzhu Biopharmaceutical Sets March 30 Board Meeting for 2025 Results and Dividend Decision
4M ago
2575
Xuanzhu Biopharm Added to Hong Kong Stock Connect, Boosting Access to Mainland Investors
PremiumCompany Announcements
Xuanzhu Biopharm Added to Hong Kong Stock Connect, Boosting Access to Mainland Investors
4M ago
2575
Xuanzhu Wins First-Line Breast Cancer Nod for Bireociclib, Extending Market Lead
PremiumCompany AnnouncementsXuanzhu Wins First-Line Breast Cancer Nod for Bireociclib, Extending Market Lead
4M ago
2575
Xuanzhu Biopharm Joins Hang Seng Composite Index, Eyes Broader Investor Base
Premium
Company Announcements
Xuanzhu Biopharm Joins Hang Seng Composite Index, Eyes Broader Investor Base
4M ago
2575
Xuanzhu Biopharmaceutical Consolidates Leadership as Chairperson Xu Yanjun Becomes General Manager
Premium
Company Announcements
Xuanzhu Biopharmaceutical Consolidates Leadership as Chairperson Xu Yanjun Becomes General Manager
6M ago
2575

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >